CFO Eisenberg Or Buys $200K in Open Market, Part of Prior PIPE
NRSN is trading near its 52-week low of $0.63 (12% above the low).
Summary
NeuroSense Therapeutics' CFO, Or Eisenberg, purchased $200,000 worth of shares in an open market transaction, signaling strong insider conviction following a recent PIPE financing.
Key Events · Ownership and Investor Activity · NRSN
-
CFO Makes Significant Open Market Purchase
Chief Financial Officer Or Eisenberg acquired 250,000 ordinary shares for $200,000 at $0.80 per share on June 16, 2026.
-
Part of Previously Announced PIPE Financing
This purchase was made pursuant to a Securities Purchase Agreement dated April 28, 2026, as part of an insider-led private placement financing.
-
Strong Insider Confidence
The $200,000 purchase represents over 0.8% of the company's market capitalization, indicating strong executive conviction.
Analysis · NRSN · Life Sciences
The Chief Financial Officer's significant open market purchase, representing over 0.8% of the company's market capitalization, demonstrates strong insider confidence. This transaction is part of the previously announced insider-led PIPE financing from April 28, 2026, providing specific detail on executive participation in the capital raise amidst recent financial challenges and Nasdaq compliance issues.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 41.2% of the 449 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NRSN was trading at $0.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $24.9M. The 52-week trading range was $0.63 to $2.52. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.